This anonymized data contains survival data from patients with resectable esophageal carcinoma to compare the outcomes of two treatment regimens: Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab.
Format
A data frame with 297 patients and 6 variables:
- arm
Treatment Arm.
- OS.time
Overall survival time in years.
- OS.event
Overall survival status (0 = censored, 1 = event).
- hist
Histological type of the tumor.
- PFS.time
Progression-free survival time in years.
- PFS.event
Progression-free survival status (0 = censored, 1 = event).
References
Ruhstaller, T., Thuss-Patience, P., Hayoz, S., Schacher, S., Knorrenschild, J. R., Schnider, A., ... & Stahl, M. (2018). Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Annals of oncology, 29(6), 1386-1393.